Announcements Trials
Browse Landscape

Phase

Phase 2 88Phase 3 40Phase 1 17Phase 1/2 14Phase 4 6Phase NA 5Phase 2/3 3Phase EARLY_PHASE1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Letrozole 7Fluorodeoxyglucose F18 7Magnetic Resonance Spectroscopy 5Blood Specimen Collection 5pembrolizumab 4atezolizumab 4Trastuzumab 4Oncolytic Virotherapy 4Bevacizumab 4palbociclib 3Saline Solution 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Biopsy 3pertuzumab 2olaparib 2Vitamin D 2Vinorelbine 2Taxes 2Sentinel Lymph Node Biopsy 2Radiotherapy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Omacor 2Neoadjuvant Therapy 2Metformin 2Lapatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Breast Neoplasms × pertuzumab × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT01875666 2020-09-04

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

UNC Lineberger Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
26 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡